ALVR - allovir.com Debt to Book Capitalization Ratio

Following the failure of final drug trials, AlloVir, Inc. (ALVR) saw its revenues dry up, forcing the business to pivot its strategy. The balance sheet capital coverage ratio relative to total debt reflects this decline, with the 0.00 metric determining this level. Stability currently relies on partnerships with medical centers for T-cell therapy, although risks of raw material dependence on Asia remain significant.

ALVR (AlloVir) Debt to Book Value history from 07/04/2022 to 03/29/2025

Summary analytical data breakdowns for allovir.com (ALVR)

- price and consensus price forecast:

Stock Price AlloVir|ALVR - Analyst Consensus Forecast

- market capitalization data:

Market Value ALVR|ALVR - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share AlloVir|ALVR - Company Net Assets|Market Capitalization to Book Value Ratio allovir.com|ALVR - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio AlloVir, Inc.|ALVR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio AlloVir|ALVR - Company Debts|Debts to Book Capitalization ALVR

Fundamental company analysis:AlloVir Bio

AlloVir, Inc. (ALVR) operates a non-cyclical business developing life-saving antiviral therapies, where success depends on regulators rather than GDP. This indicator compares the volume of borrowed funds to net assets, determining the business's ability to cover liabilities with its own property. The metric measures financial stability, excluding market noise and emotional price fluctuations. An analysis of the total debt-to-book capitalization ratio reveals hidden fundamental risks. The trend on this chart allows for an objective assessment of the issuer's debt load.

Who AlloVir, Inc. competes with